Working... Menu

Low-dose Hydrocortisone in Acutely Burned Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00149123
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : February 12, 2015
Information provided by:
Hospices Civils de Lyon

Brief Summary:
Major burns trigger the release of circulating mediators, as cytokines and endotoxin that induces a systemic inflammatory response syndrome. The cardiovascular effects are similar to those seen in septic shock. After the initial hypovolemic phase, patients with extensive burns often present a shock with increased cardiac output and reduced systemic vascular resistances. As described in septic shock, we test the hypothesis that low-dose hydrocortisone could decrease the duration of the shock period.

Condition or disease Intervention/treatment Phase
Burns Drug: hydrocortisone 200 mg/day Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: Low-dose Hydrocortisone in the Treatment of the Shock of Burned Patients
Study Start Date : April 2005
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Primary Outcome Measures :
  1. Number of patients who do not receive any more catecholamine 4 days after the beginning of the shock

Secondary Outcome Measures :
  1. Duration of catecholamine administration
  2. Doses of administered catecholamine
  3. Adrenal insufficiency incidence

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • males and females,
  • between 18 and 75 year old
  • who present a burned surface more than 30% of the body surface
  • who need catecholamine infusion
  • between J0 and J3 after the injury.

Exclusion Criteria:

  • pregnancy,
  • trauma,
  • sepsis,
  • cardiac insufficiency,
  • AIDS,
  • etomidate administration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00149123

Layout table for location information
Lyon, France, 69437
Sponsors and Collaborators
Hospices Civils de Lyon
Layout table for investigator information
Principal Investigator: Sylvie TISSOT, MD Hospices Civils de Lyon

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00149123     History of Changes
Other Study ID Numbers: 2004.354
First Posted: September 8, 2005    Key Record Dates
Last Update Posted: February 12, 2015
Last Verified: October 2007

Keywords provided by Hospices Civils de Lyon:
adrenal insufficiency
short corticotropin test

Additional relevant MeSH terms:
Layout table for MeSH terms
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Anti-Inflammatory Agents